An observational study in Neurocysticercosis, sponsored by Technical University of Munich. Completed at 1 site in Tanzania. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by Technical University of Munich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This multi-centre prospective cohort study of symptomatic patients with active neurocysticercosis (NCC) aims to identify factors related to treatment success of anthelmintic therapy.
Neurological symptom/sign and cyst resolution, quality of life, accuracy and performance of serological T. solium diagnostics and NCC-specific immunological parameter will be followed up at multiple time points in the study. The final assessment will be done six months after the end of anthelmintic treatment. This study aims to guide treatment of NCC in sub-Saharan Africa by identifying factors that are associated with treatment outcomes.
The factors that cause some people to fail complete resolution of all cysts and/or symptoms/signs are unknown.
21 studies on the registry are indexed under Neurocysticercosis; 5 are open to participants now.
Browse Neurocysticercosis studies →Technical University of Munich is the lead sponsor of 322 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with active, symptomatic neurocysticercosis in rural areas in Tanzania and Zambia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Resolution of lesions
The number of active cysts identified by CT scan after treatment
Time frame: Change in number of active cysts from before treatment to six months after treatment termination
Symptom/sign frequency
The percentage of participants who exhibit a neurological symptom/sign of NCC: chronic/severe progressive headache or epileptic seizures.
Time frame: Change of symptom/sign frequency from before treatment to six months after treatment termination
Health-related Quality of Life (all patients): WHOQOL-Bref questionnaire
The change in participants' self-reported quality of life from before to after treatment, as measured by the WHOQOL-Bref questionnaire (in all participants) \[World Health Organization Quality of Life questionnaire; consisting of 26 items\]. Quality of life is assessed by four domains - physical health, psychological, social relationships and environment. In each domain a score of 0 to 100 can be achieved. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). Domains are not summarised to an overall score.
Time frame: Change in quality of life from before treatment to six months after treatment termination
Health-related Quality of Life (epileptic patients)
The change in participants' self-reported quality of life from before to after treatment, as measured by the QOLIE-31 questionnaire \[Quality of life in epilepsy - 31 items\]. The score consists of 7 domains which all are range from 0 to 100%. Those domains are: seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive, medication effects, social function. The seven domains are then summarized to an overall score by applying weights to each category. The overall score ranges from 0 to 100% with 100% being best possible quality of life.
Time frame: Change in quality of life from before treatment to six months after treatment termination
Change in presence of T.solium-specific antigen
Change in presence of T.solium-specific antigen in the blood of patients with active neurocysticercosis
Time frame: Change in presence of T.solium-specific antigen from before treatment to six months after treatment termination
Ran from Apr 2019 to primary completion in Jan 2022, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Munich →